Pulsus Development

Early-stage strategy, before clinical development is set.

Pulsus Development is our specialist unit for early-stage assets. It answers one question: should this asset progress, and if so, how?

We work with pharma and biotech teams before the clinical plan is fixed. With a network of scientific partners, we turn preclinical data into a decision you can act on.

What we do

  • Review preclinical evidence and study design.
  • Test the mechanism of action and whether it will translate to patients.
  • Identify workable clinical hypotheses and target populations.
  • Define early development pathways.
  • Set preclinical findings against clinical and regulatory reality.

The Translational Bridge

Our Translational Bridge links early science to later use. We place each preclinical finding against three tests:

  • Is there a plausible clinical development strategy?
  • Is it feasible with regulators?
  • Would it matter in real-world treatment?

How it differs from the rest of Pulsus

The main consultancy works across clinical development and after approval. Its question is: how do we get the most value from this asset?

Pulsus Development works earlier. Its question is: should this asset go forward at all?

Where it helps

  • Asset evaluation and prioritisation.
  • Business development and licensing decisions.
  • Positioning new mechanisms.

Getting these decisions right early lowers risk later and supports more confident investment.

Tell us what you’re working on

Initial discussions are confidential and without obligation. Send a short note and we will reply.

Request a call